Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice

Angiogenesis

Volumn 10, Issue 1, 2007, Pages 23-34

  Bequet Romero, Mónica ^a   Ayala, Marta ^a   Acevedo, Boris E ^a   Rodríguez, Ernesto Galbán ^a   López Ocejo, Omar ^a   Torrens, Isis ^a   Gavilondo, Jorge V ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Angiogenesis; Cancer; DNA immunization; Immunotherapy; VEGF

Indexed keywords

NAKED DNA; VASCULOTROPIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER PREVENTION; CELL DENSITY; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA IMMUNIZATION; EMBRYO; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LUNG CARCINOMA; MELANOMA; METASTASIS; MITOSIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RECEPTOR BINDING; SPLEEN CELL; SURVIVAL; TUMOR CELL; TUMOR GROWTH; VESSEL;

ANGIOGENESIS INHIBITORS; ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS;

EID: 33847673267     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-006-9062-9     Document Type: Article

References (41)

1. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
2. Folkman J (2003) Angiogenesis and apoptosis. Semin Cancer Biol 13:159-167
3. Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263-272
4. Ferrara N, Gerber HP, Lecouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
5. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328-335
6. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
7. Midgley R, Kerr D (2005) Bevacizumab - current status and future directions. Ann Oncol 16:999-1004
8. Jayson GC, Zweit J, Jackson A et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484-1493
9. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE (2002) A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5:35-44
10. Zhu Z, Hattori K, Zhang H et al (2003) Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17:604-611
11. Tartour E, Fridman WH (2000) Cancer vaccine 2000. Immunol Lett 74:1-3
12. Wei YQ, Huang MJ, Yang L et al (2001) Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98:11545-11550
13. Zagury D, Gallo RC (2004) Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today 9:72-81
14. Liu JY, Wei YQ, Yang L et al (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102:1815-1823
15. Lu F, Qin ZY, Yang WB, Qi YX, Li YM (2004) A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo. World J Gastroenterol 10:2039-2044
16. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99:7009-7014
17. Reisfeld RA, Niethammer AG, Luo Y, Xiang R (2004) DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int Arch Allergy Immunol 133:295-304
18. Herrera AM, Rodriguez EG, Hernandez T, Sandez B, Duarte CA (2000) A family of compact plasmid vectors for DNA immunization in humans. Biochem Biophys Res Commun 279:548-551
19. Lin KY, Guarnieri FG, Staveley-O'Carroll KF et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26
20. Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M (1984) The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 34:567-573
21. Rodriguez EG, Vazquez DM, Herrera AM, Duarte CA (2003) Enhanced cell-mediated INF-gamma secreting activity against the HIV IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering. Biochem Biophys Res Commun 308:713-718
22. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF (1998) Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 273:29979-29985
23. Ojalvo AG, Seralena A, Vázquez R et al (2003) Therapeutic angiogenesis following intramuscular gene transfer of vascular endothelial growth factor 121 in a dog model of hindlimb ischemia. Electronic J Biotechnol 6:208-222
24. Li Y, Wang MN, Li H et al (2002) Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195:1575-1584
25. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555-556
26. Morera Y, Lamdan H, Bequet M et al (2006) Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein. Biotechnol Appl Biochem 44:45-53
27. Li Z, Zhang H, Fan X et al (2006) DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24:4565-4568
28. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC (1998) Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161:3042-3049
29. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160:870-876
30. Sun S, Kishimoto H, Sprent J (1998) DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med 187:1145-1150
31. Plum SM, Fogler WE (2004) Anti-angiogenic vaccines as a treatment modality for cancer. Curr Opin Investig Drugs 5:1243-1246
32. Brand A (2002) Immunological aspects of blood transfusions. Transpl Immunol 10:183-190
33. Niethammer AG, Xiang R, Becker JC et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369-1375
34. Ferrara N, Winer J, Burton T et al (1993) Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 91:160-170
35. Agnantis NJ, Goussia AC, Batistatou A, Stefanou D (2004) Tumor markers in cancer patients. an update of their prognostic significance. Part II. In Vivo 18:481-488
36. Shinkaruk S, Bayle M, Lain G, Deleris G (2003) Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anti -Canc Agents 3:95-117
37. Keyt BA, Nguyen HV, Berleau LT et al (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptorselective VEGF variants by site-directed mutagenesis. J Biol Chem 271:5638-5646
38. Kim KJ, Li B, Houck K, Winer J, Ferrara N (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64
39. Kitamoto Y, Tokunaga H, Miyamoto K, Tomita K (2002) VEGF is an essential molecule for glomerular structuring. Nephrol Dial Transplant 17(Suppl 9):25-27
40. Herbst RS, Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9 Suppl 9(Suppl 1):19-26
41. Sandler AB, Johnson DH, Herbst RS (2004) Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10:4258s-4262s